(Sharecast News) - Avacta Therapeutics said on Monday that it had made strong progress across its oncology pipeline in the first half of 2026, including the start of clinical work for its second-generation preCISION drug candidate AVA6103.
The AIM-traded clinical-stage biopharmaceutical company said the first patient was treated in March in...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE